免疫蛋白酶体抑制剂及基因敲除减轻小鼠自身免疫性心肌炎的心脏特异性免疫反应
该研究在小鼠TnI导向的自身免疫性心肌炎模型中,通过敲除免疫蛋白酶体亚基(LMP2、LMP7、MECL1)或使用抑制剂ONX 0914,观察到心脏炎症、促炎细胞因子、IL-17产生和纤维化减轻,心功能改善。机制涉及脾脏效应CD4+ T细胞与调节性CD4+ T细胞平衡改变及PD-1表达升高。在2例ICI相关心肌炎中亦观察到类似的自身免疫特征。
要点
- 免疫蛋白酶体缺陷减轻小鼠TnI自身免疫性心肌炎的心脏病理。
- ONX 0914可预防或逆转小鼠TnI-AM的诱导与进展。
- ICI相关心肌炎病例中可见心脏特异性自身免疫反应激活。
核心结论
- 免疫蛋白酶体抑制剂在小鼠模型中通过逆转心脏特异性自身免疫反应,显示出辅助管理人类自身免疫性心肌炎的潜力,可能包括ICI相关心脏自身免疫患者。
研究设计与样本
- 研究使用缺乏全部3个免疫蛋白酶体亚基(triple-ip-/-)或缺乏LMP2和LMP7基因的小鼠,通过心脏TnI肽免疫诱导TnI导向的自身免疫性心肌炎(TnI-AM),一种CD4+ T细胞介导的疾病。
- 另在TnI-AM诱导前或自身免疫性心肌炎建立后,使用免疫蛋白酶体抑制剂ONX 0914治疗小鼠。
- 研究调查了实验性TnI-AM和2例ICI相关心肌炎病例中定义心脏特异性自身免疫的免疫参数。
主要发现
- 所有免疫蛋白酶体缺陷品系显示自身免疫相关心脏病理减轻,包括炎症减少、促炎和趋化细胞因子降低、IL-17产生减少和纤维化形成减少。
- LMP7-/-小鼠保护免受TnI导向的自身免疫心脏病理并改善心脏功能,涉及脾脏效应CD4+ T细胞与调节性CD4+ T细胞平衡改变,LMP7-/-小鼠的CD4+ T细胞显示抑制性PD-1分子表达升高。
- 用ONX 0914处理TLR2 engaged和TLR7/TLR8 engaged的CD14+单核细胞,阻断免疫蛋白酶体蛋白水解,减少促炎细胞因子反应,从而减少自身反应性CD4+ T细胞扩增的刺激。
- 在小鼠中,ONX 0914治疗逆转心脏自身免疫病理,当自身反应性CD4+ T细胞致敏时预防TnI-AM的诱导和进展。
- 实验性TnI-AM的自身免疫特征(高免疫蛋白酶体表达、IgG沉积、心脏组织IL-17产生和TnI导向的体液自身免疫反应)也存在于2例ICI相关心肌炎病例中,表明ICI治疗激活了心脏特异性自身免疫反应。
临床怎么用
- 免疫蛋白酶体抑制剂可能作为管理自身免疫性心肌炎(包括ICI相关心脏自身免疫)的潜在策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is often accompanied by immune-related pathology, with an increasing occurrence of high-risk ICI-related myocarditis. Understanding the mechanisms involved in this side effect could enable the development of management strategies. In mouse models, immune checkpoints, such as PD-1 (programmed cell death protein 1), control the threshold of self-antigen responses directed against cardiac TnI (troponin I). We aimed to identify how the immunoproteasome, the main proteolytic machinery in immune cells harboring 3 distinct protease activities in the LMP2 (low-molecular-weight protein 2), LMP7 (low-molecular-weight protein 7), and MECL1 (multicatalytic endopeptidase complex subunit 1) subunit, affects TnI-directed autoimmune pathology of the heart. METHODS: TnI-directed autoimmune myocarditis (TnI-AM), a CD4+ T-cell-mediated disease, was induced in mice lacking all 3 immunoproteasome subunits (triple-ip-/-) or lacking either the gene encoding LMP2 and LMP7 by immunization with a cardiac TnI peptide. Alternatively, before induction of TnI-AM or after establishment of autoimmune myocarditis, mice were treated with the immunoproteasome inhibitor ONX 0914. Immune parameters defining heart-specific autoimmunity were investigated in experimental TnI-AM and in 2 cases of ICI-related myocarditis. RESULTS: All immunoproteasome-deficient strains showed mitigated autoimmune-related cardiac pathology with less inflammation, lower proinflammatory and chemotactic cytokines, less interleukin-17 production, and reduced fibrosis formation. Protection from TnI-directed autoimmune heart pathology with improved cardiac function in LMP7-/- mice involved a changed balance between effector and regulatory CD4+ T cells in the spleen, with CD4+ T cells from LMP7-/- mice showing a higher expression of inhibitory PD-1 molecules. Blocked immunoproteasome proteolysis, by treatment of TLR2 (Toll-like receptor 2)-engaged and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)-engaged CD14+ monocytes with ONX 0914, diminished proinflammatory cytokine responses, thereby reducing the boost for the expansion of self-reactive CD4+ T cells. Correspondingly, in mice, ONX 0914 treatment reversed cardiac autoimmune pathology, preventing the induction and progression of TnI-AM when self-reactive CD4+ T cells were primed. The autoimmune signature during experimental TnI-AM, with high immunoproteasome expression, immunoglobulin G deposition, interleukin-17 production in heart tissue, and TnI-directed humoral autoimmune responses, was also present in 2 cases of ICI-related myocarditis, demonstrating the activation of heart-specific autoimmune reactions by ICI therapy. CONCLUSIONS: By reversing heart-specific autoimmune responses, immunoproteasome inhibitors applied to a mouse model demonstrate their potential to aid in the management of autoimmune myocarditis in humans, possibly including patients with ICI-related heart-specific autoimmunity.
引用
- Bockstahler M, Fischer A, Goetzke CC, et al. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. Circulation. 2020. PMID: 32160764. doi:10.1161/CIRCULATIONAHA.119.043171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。